About me
Based at Takeda’s Cambridge, Massachusetts, R&D campus, Christopher Arendt is responsible for oversight of Takeda’s Research and Early Development portfolio across Takeda’s core therapeutic areas of Gastroenterology and
Inflammation, Oncology, and Neuroscience. Prior to his current role, Christopher led the Oncology Cell Therapy and Therapeutic Area Unit and was responsible for Takeda’s oncology R&D strategy and for all development programs from candidate selection through lifecycle management, via cross-functional program teams. He helped reshape Takeda’s pipeline with a strong network of top-tier global collaborators, emphasizing emerging science leveraging a breadth of mechanisms and modalities, including allogenic innate immune cell therapies, antibody-targeted small molecules and oligonucleotides, and cutting-edge biologics.
Christopher is a Ph.D. Immunologist who carried out postdoctoral training with Dan Littman at New York University Medical Center. Prior to joining Takeda, Christopher spent more than 13 years at Sanofi, where he led global teams advancing novel immunotherapies for cancers and inflammatory diseases.
